Novo Nordisk A/S Increases Stake in Innate Pharma SA

Novo Nordisk A/S has filed an amendment to its Schedule 13G, disclosing an increased beneficial ownership of 9.65% in Innate Pharma SA. This amounts to 8,895,649 ordinary shares, with sole voting and dispositive power over these shares. The filing indicates that Novo Nordisk A/S, a Denmark-based company, now holds a significant stake in Innate Pharma SA, a French biopharmaceutical company. The amendment was signed by Karsten Munk Knudsen, Chief Financial Officer of Novo Nordisk A/S, and was filed on October 21, 2025. This filing is an amendment to a previous filing made on July 14, 2025, and is in accordance with Rule 13d-1(d).